Phoenix Biotech Acquisition Debt to Equity

Phoenix Biotech Acquisition posts a debt-to-equity ratio of -0.28. That is below the sector sector average of 0.2. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a debt-to-equity ratio near 0.2 is typical. Phoenix Biotech Acquisition's -0.28 is lower that level. That is roughly 240.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Phoenix Biotech Acquisition's debt-to-equity ratio of -0.28 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for PBAX's debt-to-equity ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 0.2), and (3) consistency with growth and profitability. This page covers the first two; Phoenix Biotech Acquisition's other metric pages and overview cover the third.